Plain-English translation of NCT06686030 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called AK112, which works by targeting two different pathways in cancer cells. The study combines AK112 with standard treatments and/or another medication called to see if this combination is more effective and safe for people whose ovarian cancer has come back after responding to prior platinum-based .
Ovarian cancer that returns after initial treatment can be difficult to manage, and doctors are looking for better options. This trial is exploring whether combining this new medication with existing treatments can help stop the cancer from growing and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the new medication combined with for 4–6 cycles, followed by maintenance treatment with the medication alone or in combination with , depending on which treatment group you're assigned to. You would need to visit the study center regularly for infusions, blood tests, imaging scans, and safety monitoring throughout the treatment period. Your doctor will also ask you to provide a tissue sample from your previous cancer biopsy for research purposes.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Akeso
Enrollment target
~150 participants
Started
February 2025
Primary completion
October 2027
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Liu, M.D.
Akeso
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.